| Market Cap | 26.97M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -110.25M | Forward P/E | -6.42 | EPS next Y | - | 50D Avg Chg | -19.00% |
| Sales | 10.67M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -20.00% |
| Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -64.00% |
| Recommedations | 2.00 | Quick Ratio | 0.09 | Shares Outstanding | 6.27M | 52W Low Chg | 65.00% |
| Insider Own | 2.16% | ROA | -52.64% | Shares Float | 6.04M | Beta | - |
| Inst Own | 0.10% | ROE | -243.12% | Shares Shorted/Prior | 44.48K/27.99K | Price | 4.30 |
| Gross Margin | 69.30% | Profit Margin | - | Avg. Volume | 21,211 | Target Price | - |
| Oper. Margin | -871.13% | Earnings Date | May 16 | Volume | 35,704 | Change | -3.15% |
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is headquartered in Shanghai, the People's Republic of China.